Pulmonx Files Annual Report, Details $60M Debt Facility and Warrants to Secure Liquidity

summarizeSummary

Pulmonx reported FY2025 results with increased revenue but continued net losses, and detailed a new $60 million debt facility with warrants, which is critical for its liquidity and ongoing operations.

check_boxKey Events

• Fiscal Year 2025 Financial Performance

  Pulmonx reported revenue of $90.5 million for the year ended December 31, 2025, an 8.0% increase from $83.8 million in 2024. The company incurred a net loss of $54.0 million, an improvement from a $56.4 million net loss in 2024.

• New $60 Million Term Loan Facility

  Subsequent to year-end, on March 2, 2026, the company secured a new senior secured term loan facility of up to $60.0 million from Perceptive Credit Holdings V, LP. An initial $40.0 million was drawn immediately, with an additional $20.0 million available in two tranches contingent on revenue milestones. This facility matures on March 2, 2031, and carries an interest rate of 7.00% plus the greater of one-month term SOFR or 3.75%. The previous CIBC Loan was fully repaid.

• Warrant Issuance

  In connection with the new term loan, Pulmonx issued warrants to Perceptive to purchase up to 1,000,000 shares of common stock at an exercise price of $1.92 per share, representing a 25% premium to the 10-day volume weighted average price preceding the closing date. Additional warrants will be issued for future draws.

• Liquidity and Going Concern

  Management explicitly stated that the existing cash and cash equivalents, combined with the new debt refinancing, are expected to fund operations for at least the next 12 months from the issuance date of the financial statements.

auto_awesomeAnalysis

This annual report provides the full audited financial results for fiscal year 2025, showing continued revenue growth but persistent net losses and negative cash flow from operations. The most significant development, detailed as a subsequent event, is the new $60 million senior secured term loan facility, which includes an immediate $40 million draw and the issuance of 1,000,000 warrants. While the core details of this financing were previously disclosed in recent 8-K filings, this 10-K formalizes the transaction and explicitly links it to the company's ability to fund operations for the next 12 months, addressing going concern considerations. The financing provides crucial short-term liquidity but introduces additional debt and potential dilution from the warrants, reflecting the company's ongoing need for capital to support its growth and product development initiatives.